These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 14981964

  • 21. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
    Liang A, Zhang H, Fang Y, Li Y, Zhu D, Chen F, Lu H, Fu J, Bo L.
    Pharmazie; 2012 Jul; 67(7):635-8. PubMed ID: 22888522
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
    Kreis W, Chaudhri F, Chan K, Allen S, Budman DR, Schulman P, Weiselberg L, Freeman J, Deere M, Vinciguerra V.
    Cancer Res; 1985 Dec; 45(12 Pt 1):6498-501. PubMed ID: 3864533
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T, Kawai Y, Goto N, Kishi S, Imamura S, Yoshida A, Urasaki Y, Fukushima T, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Ohshima A, Yoshida K, Sato T, Miyazaki S, Yanagisawa M, Nakayama Y, Takahashi T, Mamiya S, Fukusima Y, Miura AB.
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
    [Abstract] [Full Text] [Related]

  • 29. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT, Jiang SY, Li BS, Yang LL.
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [Abstract] [Full Text] [Related]

  • 30. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
    Spriggs D, Robbins G, Ohno Y, Kufe D.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6532-6. PubMed ID: 3479246
    [Abstract] [Full Text] [Related]

  • 31. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP, Willemze R, Honders W, vd Hoorn F, Edelbroek PM.
    Semin Oncol; 1985 Jun 15; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [Abstract] [Full Text] [Related]

  • 32. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.
    Capizzi RL, White JC, Powell BL, Perrino F.
    Semin Hematol; 1991 Jul 15; 28(3 Suppl 4):54-69. PubMed ID: 1780754
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

  • 34. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 01; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 35. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
    Donehower RC, Karp JE, Burke PJ.
    Cancer Treat Rep; 1986 Sep 01; 70(9):1059-65. PubMed ID: 3461882
    [Abstract] [Full Text] [Related]

  • 36. [Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C].
    Kamiya K, Uchida M, Ueda T, Nakamura T.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul 20; 25(7):1419-27. PubMed ID: 2212834
    [Abstract] [Full Text] [Related]

  • 37. Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis.
    Kobayashi S, Sakai H, Tomiazwa T, Koiso H, Kim K, Ueki K, Tamura J, Yano S, Naruse T, Karasawa M.
    J Med; 1999 Jul 20; 30(1-2):101-9. PubMed ID: 10515246
    [Abstract] [Full Text] [Related]

  • 38. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
    Takahashi I, Nakada H, Hayashi N, Sekito N, Inagaki T, Aoyama S, Nonaka K, Ohmoto E, Kobayashi Y, Uchida K.
    Gan To Kagaku Ryoho; 1986 Sep 20; 13(9):2780-5. PubMed ID: 3463249
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E, Braess J, Ramsauer B, Unterhalt M, Kaufmann C, Wilde S, Schüssler M, Hiddemann W.
    Leukemia; 1995 Jun 20; 9(6):1085-90. PubMed ID: 7596174
    [Abstract] [Full Text] [Related]

  • 40. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB.
    Jpn J Clin Oncol; 2005 Oct 20; 35(10):612-6. PubMed ID: 16172175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.